In TRUTH, Wall Street STOCKS are all as worthless as any CRYPTO, as regards any underlying SUBSTANTIVE value!!!
It's not a real market. The economy is in the shitter lol
CATX: As they TRASH the price now!! DAMN-IT!! (But, it still could fly --- I didn't toss 'The Farm' at it, of course.)
WHAT A WILD MARKET PLACE!!!
Holy smokes! Nice find brother!
Oppenheimer raises Target to $1.20 a 150PERCENT increase. $CATX at a price of $.46 Oppenheimer raised it's price target to 1.2 showing a 150 projected upside potential from that price. Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.20 Maintains buy Rating
Oooooops, didn’t take long for that to be wiped out……LMFAOOOOOO
Holding CATTURDX = LOST YOUR SHIRT Hahahaha Funny and Puny...... holders just haven't realized it yet.
CATX TURDS you will Loose your shirts, you can bank on it, Go ahead Buy in some more, you can bank on loosing your shirt.
CATTURDX= Loose your Shirt. You can bank on it………
3rd NEW 52 WEEK HIGH in just over a week.
New 52 week high Today.........It has been a strong steady rise in price for the last week. One hopes CATX , formerly ISR, is going up based on all the recent news and activities. Thanks for the message Prudent Cap.
Center: Thiis ticker post-merger is now Perspective Therapeutics, Inc (CATX) and is now trading up inthe .47+ range. This board is thus reflecting an inaccurate low share price and ticker symbol. Perhaps you should update and convert it so correct share pricing is reported here. Just food for thought. Congrats on the merger and significant gains.
$1600 profit on 10grand in ONE DAY How's that for buyer beware? HaHa.
also no dilution coming from A/S that were already used for the CASH FREE Merger, of course one would have to read to know that.
WOW, a whole nickle, mighty impressive…………LMFAOOOOOO
Dilution incoming, look out below…….
UP 16 PERCENT Today on good volume....Read it and Weep!!!
Looks like yet another day of zero volume for ISOTURD……..LMFAOOOOOO
Perhaps you should check CATX but you probably knew that.
Yep, ZERO volume since February 21, 2023………..ISOTURD, a big fat. ZERO……..
ISR Historical Summary
Period Open High Low VWAP Avg. Daily Vol Change %
1 Week 0.00 0.00 0.00 0.00 0 0.00 0.0%
Date Close Change Change (%) Open High Low Volume
Mar 01 2023 0.384 0.00 0.0% 0.384 0.384 0.384 0
Feb 28 2023 0.384 0.00 0.0% 0.384 0.384 0.384 0
Feb 27 2023 0.384 0.00 0.0% 0.384 0.384 0.384 0
Feb 24 2023 0.384 0.00 0.0% 0.384 0.384 0.384 0
Feb 23 2023 0.384 0.00 0.0% 0.384 0.384 0.384 0
Feb 22 2023 0.384 0.00 0.0% 0.384 0.384 0.384 0
Feb 21 2023 0.384 0.00 0.0% 0.384 0.384 0.384 0
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
8:10 AM ET Feb-06-2023
The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals
RICHLAND, Wash. & CORALVILLE, Iowa--(BUSINESS WIRE)-- Isoray, Inc. (ISR.NaE) , a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies’ focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor sites. Viewpoint Molecular Targeting CEO Thijs Spoor has been named Chief Executive Officer and outgoing Isoray (ISR.NaE) CEO Lori Woods assumed the role of Chairperson of the Board of Directors of the combined companies. The closing of the all-stock transaction became effective on February 3, 2023.
Outgoing Isoray (ISR.NaE) CEO Lori Woods said, “This merger represents an important milestone for Isoray (ISR.NaE). The merger with Viewpoint Molecular Targeting demonstrates our commitment to build on our shared belief of treating cancers from the inside out while providing personalized targeted treatment options for cancer patients. We look forward to delivering a path forward that speaks to the continued growth of the combined companies benefitting patients and the doctors who treat them, while increasing stockholder value.”
Incoming Isoray (ISR.NaE) CEO Thijs Spoor commented, “The merger of Isoray (ISR.NaE) and Viewpoint represents a powerful combination of two complementary businesses in the field of radiopharmaceuticals. The mission of the combined company is to further develop the role of Cesium-131 for the treatment of a variety of cancers while we expand on our exciting and novel pipeline of proprietary targeting peptides to diagnose tumors in order to deliver powerful Targeted Alpha Therapies (TAT’s). The use of alpha-particle radiation with proprietary targeted delivery agents has the potential to transform the treatment paradigm of patients suffering from early stage cancers.”
About the Merger
At the closing of the merger, each issued and outstanding share of common stock of Viewpoint was converted into 3.1642 shares of Isoray (ISR.NaE) common stock for a total of 136,545,075 shares, or approximately 49%, of the 278,657,841 shares of outstanding common stock of Isoray (ISR.NaE). Other than cash paid in lieu of fractional shares which amounted to $14.80, there was no cash consideration paid in connection with the merger.
Concurrent with the closing of the merger, the size of Isoray’s Board of Directors was increased to five members comprised of Lori Woods (Chairperson), Thijs Spoor, Dr. Frank Morich, Robert Williamson, and Michael McCormick.
About Isoray (ISR.NaE)
Isoray, Inc. (ISR.NaE) is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc. (ISR.NaE), through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and Twitter.
January 2, 2023 pps $.2471
February 2, 2023 pps $.40
Math seems a bit distorted I’d say…………LMFAOOOOOO
That’s odd, ISOTURD history will reflect loaded up at $.35. Averaged down in the $.2x area I guess………Math seems a bit distorted………LMFAOOOOOO.
Exciting!! bought 50,000/sh at .2 sold 40,000 at .4 still have 10,000sh from that one trade. now that's how you make money and support a good company with a good cause. Got my 10 grand back, made 6 grand, with 10,000shares on the houses money....SWEET!!
Market likes the Merger news $$ISR up on increased Volume
A/S increase incoming
Massive dilution will be on the increase here. From $2.81 to $0.45 to $0.40 to $0.35 to $0.30 to under $0.30 bag holders galore with ISOTURD.
Those investors who went in deep at $0.35 range are getting and going to get slaughtered and gutted like a pig.
Don’t look now but ISOTURD is red, again………LMFAOOOOOO
Hahahaha………ISOTURD, From $2.81 to $0.45 to $0.40 to $0.35 to $0.30 to $0.25, bag holders galore with ISOTURD.
This garbage not to far from a 5 year low. Real and heavier dilution coming to ISOTURD………..LMFAOOOOOO
Any investors holding this for years are getting slaughtered……..LMFAOOOOOO